Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.

Pharmacogenetics and genomics - 1 Dec 2011

Coller Janet K, Cahill Sharon, Edmonds Carolyn, Farquharson Aaron L, Longo Marie, Minniti Rinaldo, Sullivan Thomas, Somogyi Andrew A, White Jason M

Abstract excerpt

Given the evidence from retrospective studies indicating that alcohol-dependent patients with homozygous or heterozygous A118G variant of the μ-opioid receptor, OPRM1, gene have significantly better outcomes when treated with naltrexone; this study examined this prospectively in 100 alcohol-dependent participants prescribed naltrexone for 12 weeks and offered six sessions of cognitive-behavioral therapy or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Australia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognitive Behavioral Therapy

Share to Naltrexone

Share to Narcotic Antagonists

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Share to White People

Source

Identifiers

PMID: 21946895
DOI: 10.1097/FPC.0b013e32834c5445

Genes

OPRM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.PMID 21946895Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.Semantic proximity Read ↗

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.